Please login to the form below

Not currently logged in
Email:
Password:

Roch Doliveux named chair of IMI

UCB’s chief executive has served on the board of the Innovative Medicines Initiative since 2010

UCB Roch Doliveux Innovative Medicines InitiativeUCB's chief executive Roch Doliveux has been appointed chair of the Innovative Medicines Initiative's (IMI) governing board.

He has served as a board member since May 2010 and also sits on the board of one of IMI's founding partners the European Federation of Pharmaceutical Industries and Associations (EFPIA).

Doliveux said: "The biopharmaceutical industry has reached an inflection point where public-private partnerships, bringing academic and industry knowledge together, are paving the way to better respond to new healthcare needs and bring safer, more efficacious and cost-effective treatments to patients.

“EFPIA considers IMI as a key instrument to implement the new business models which will ensure the sustainability of the pharmaceutical industry and increase the wellbeing of patients across Europe.''

As chair, Doliveux "will be in a unique position to move forward his vision for the future of the pharmaceutical industry based on open innovation and precompetitive research", IMI's executive director Michel Goldman said.

"The early achievements of the on-going IMI projects demonstrate that this new model based on public-private partnership is already successful".

The IMI currently funds 30 projects with a combined budget of around €600m covering drug safety and efficacy, knowledge management, and education/training.

This week it unveiled plans for European pharma companies to make 300,000 compounds from their in-house libraries available to academic researchers as part of a €169m scheme.

The IMI was set up in 2010 as a public-private partnership between the European Union (EU) and European industry organisation EFPIA, with the aim of speeding the discovery and development of new medicines.

8th March 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
90TEN

90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...

Latest intelligence

DEMAND DIVERSITY REPORT 02: Why is the LGBTQ+ community facing poorer health outcomes due to COVID-19?
We’re all aware that clinical trials have been discussed more widely since the COVID-19 pandemic. While that’s a great thing for raising awareness of clinical trials in general, it’s also...
CHECKLIST 04: Let’s make your patient recruitment strategies a success
From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...

Infographics